Quantitation of hydroxyproline in bone by gas chromatography-mass spectrometry

Growth Rate and Bone Hydroxyproline Concentration in Turkeys Fed with a Silage-Composed Diet Modified with Different Diet Cation-Anion Differences (DCADs)

Simple Summary

In this study, we point to the possibility of using dietary cation–anion difference manipulation to improve growth rates and bone condition, especially in the last phase of poultry turkey husbandry, when birds have many bone abnormalities.

Abstract

Our goal was to determine the responses of body weight (BW) and bone hydroxyproline (Hyp) concentration in turkeys fed a corn silage (CS) diet with different values of dietary cation–anion differences (DCADs). The turkeys (n = 90) were divided into five groups and fed as follows: group A (control)—standard diet (SD) (60%) plus CS (40%); group B—SD (60%), CS (40%) plus 240 g of CaCl₂ per 100 kg of diet; group C—SD (60%), CS (40%) plus 480 g of CaCl₂ per 100 kg of diet; group D—SD (60%), CS (40%) plus 240 g of NaHCO₃ per 100 kg of diet; group E—SD (60%), CS (40%) plus 480 g NaHCO₃ per 100 kg of diet. The addition of a lesser amount of CaCl₂ lowered the DCAD, which ranged between 52.5 ± 4.19 and 91.14 ± 3.14 mEq/kg DM. An increased content of CaCl₂ led to high negative values of DCAD. NaHCO₃ supplemented in both doses resulted in a significant elevation of DCAD. Compared to each experimental group, feeding birds with a diet supplemented only with CS resulted in a lower BW. Addition of CaCl₂ or NaHCO₃ to the diet improved BW, but only CaCl₂ addition enhanced the bone Hyp amount. In conclusion, we suggest that an anionic diet with low DCAD can prevent bone abnormalities in large turkeys, especially in the final course of production.

Metabolomic biomarkers of low BMD: a systematic review

Due to the metabolic nature of osteoporosis, this study was conducted to identify metabolomic studies investigating the metabolic profile of low bone mineral density (BMD) and osteoporosis. A comprehensive systematic literature search was conducted through PubMed, Web of Science, Scopus, and Embase databases up to April 08, 2020, to identify observational studies with cross-sectional or case-control designs investigating the metabolic profile of low BMD in adults using biofluid specimen via metabolomic platform. The quality assessment panel specified for the "omics"-based diagnostic research (QUADOMICS) tool was used to estimate the methodologic quality of the included studies. Ten untargeted and one targeted approach metabolomic studies investigating biomarkers in different biofluids through mass spectrometry or nuclear magnetic resonance platforms were included in the systematic review. Some metabolite panels, rather than individual metabolites, showed promising results in differentiating low BMD from normal. Candidate metabolites were of different categories including amino acids, followed by lipids and carbohydrates. Besides, certain pathways were suggested by some of the studies to be involved. This systematic review suggested that metabolic profiling could improve the diagnosis of low BMD. Despite valuable findings attained from each of these studies, there was great heterogeneity regarding the ethnicity and age of participants, samples, and the metabolomic platform. Further longitudinal studies are needed to validate the results and confirm the predictive role of metabolic profile on low BMD and fracture. It is also mandatory to address and minimize the heterogeneity in future studies by using reliable quantitative methods. Summary: Due to the metabolic nature of osteoporosis, researchers have considered metabolomic studies recently. This systematic review showed that metabolic profiling including different categories of metabolites could improve the diagnosis of low BMD. However, great heterogeneity was observed and it is mandatory to address and minimize the heterogeneity in future studies.

Enzyme-free impedimetric biosensor-based molecularly imprinted polymer for selective determination of L-hydroxyproline

This study first reported enzyme-free impedimetric biosensor-based molecularly imprinted polymers for selective and sensitive determination of L-hydroxyproline (L-hyp), a biomarker for the early diagnosis of bone diseases. In recent study, utilizing a single 3-aminophenylboronic acid (3-APBA) to create imprinted surfaces could result in a strong interaction and difficulty in removal of a template molecule. Hence, a mixture of monomer solution containing 3-APBA and o-phenylenediamine (OPD) in the presence of the L-hyp molecule was co-electropolymerized onto the screen-printed electrode using cyclic voltammetry (CV) to eradicate this mentioned limitation. The detection principle of this sensor is relied on alteration of mediator's charge transfer resistance (R_ct) that could be obstructed by L-hyp occupied in imprinted surface. The successfully fabricated biosensor was explored by scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), and confocal scanning microscopy. Furthermore, the effect of polymer composition on the R_ct response was systematically investigated. The result exhibited that the mixture of monomers could provide the highest change of R_ct due to high selectivity from esterification of 3-APBA and from hydrogen bond of OPD surrounding the template. The sensor showed a significant increase in R_ct in the presence of L-hyp, whereas no observable resistance change was detected in the absence thereof. The calibration curve was obtained in the range from 0.4 to 25 μg mL^-1 with limits of detection (3SD_blank/Slope) and quantification (10SD_blank/Slope) of 0.13 and 0.42 μg mL^-1, respectively. This biosensor exhibited high selectivity and sensitivity and was successfully applied to determine L-hyp in human serum samples with satisfactory results.

Metabolomics-based profiles predictive of low bone mass in menopausal women

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis. To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss.

Association between the metabolome and bone mineral density in pre- and post-menopausal Chinese women using GC-MS

The present study describes for the first time, a metabolic profile reflecting the osteoporosis progression in 364 pre- and postmenopausal Chinese women using GC-MS. In order to accurately evaluate the dynamic changes of metabolites along with estrogen deficiency and osteoporosis progression, we divided these subjects into the following four groups: premenopausal women with normal bone mass density (BMD, group I), postmenopausal women with normal BMD (group II), postmenopausal women with osteopenia (group III) and postmenopausal women with osteoporosis (group IV), according to their menopause or low BMD status. Principal component analysis (PCA) and Partial least squares-discriminant analysis (PLS-DA) were used to evaluate the associations of metabolic changes with low BMD or estrogen deficiency. Twelve metabolites identified by the PLS-DA model were found to be able to differentiate low BMD groups from normal BMD groups. Of the 12 metabolites, five free fatty acids (LA, oleic acid, AA and 11,14-eicosadienoic acid) have the most potential to be used as osteoporosis biomarkers due to their better correlations with BMD, and high sensitivity and specificity in distinguishing the low BMD groups from the normal BMD groups calculated by the receiver operating characteristic curve (ROC). The lipid profile may be useful for osteoporosis prediction and diagnosis.

Hydroxyproline quantification for the estimation of collagen in tissue using multiple reaction monitoring mass spectrometry

Collagens are highly abundant mammalian proteins that contain a high content of hydroxylated amino acids such as hydroxyproline. We have exploited the high hydroxyproline content of collagen and developed a method for hydroxyproline quantification as a measure of collagen content in muscle samples. The novel method utilizes a highly selective and sensitive method of multiple reaction monitoring (MRM) by mass spectrometry. The analytical method is simple, rapid (5min), convenient (no derivatization), precise (<17% RSD), accurate (90-108%), sensitive (4.88nmol/L) and linear (R(2)>0.999) over three orders of magnitude (5-5000nmol/L).

Analysis of hydroxyproline isomers and hydroxylysine by reversed-phase HPLC and mass spectrometry

Collagens, the most abundant mammalian proteins, contain a high content of hydroxylated amino acids, such as, 3- and 4-cis-/trans-hydroxyproline (Hyp) and 5-hydroxylysine (Hyl). Whereas the global content of 4-Hyp was studied by amino acid analysis, no technique to determine all five hydroxyamino acids simultaneously in collagens has been reported. Here, we report the separation of all five hydroxyamino acids as well as two Hyp epimers from all other proteinogenic amino acids after derivatization with N(2)-(5-fluoro-2,4-dinitrophenyl)-l-valine amide (l-FDVA) by RPC-UV-ESI-MS. The general applicability of this method is shown for three Hyp-containing peptides as well as collagen type I.

Effect of rapamycin on hepatic osteodystrophy in rats with portasystemic shunting

AIM: To study if T-cell activation related to portasystemic shunting causes osteoclast-mediated bone loss through RANKL-dependent pathways. We also investigated if T-cell inhibition using rapamycin would protect against bone loss in rats.

METHODS: Portasystemic shunting was performed in male Sprague-Dawley rats and rapamycin 0.1 mg/kg was administered for 15 wk by gavage. Rats received powderized chow and supplemental feeds to prevent the effects of malnutrition on bone composition. Weight gain and growth was restored after surgery in shunted animals. At termination, biochemical parameters of bone turnover and quantitative bone histology were assessed. Markers of T-cell activation, inflammatory cytokine production, and RANKL-dependent pathways were measured. In addition, the roles of IGF-1 and hypogonadism were investigated.

RESULTS: Portasystemic shunting caused low turnover osteoporosis that was RANKL independent. Bone resorbing cytokine levels, including IL-1, IL-6 and TNFα, were not increased in serum and TNFα and RANKL expression were not upregulated in PBMC. Portasystemic shunting increased the circulating CD8+ T-cell population. Rapamycin decreased the circulating CD8+ T-cell population, increased CD8+ CD25+ T-regulatory cell population and improved all parameters of bone turnover.

CONCLUSION: Osteoporosis caused by portasystemic shunting may be partially ameliorated by rapamycin in the rat model of hepatic osteodystrophy.

Determination of 1,2-dibromoethane, 1,4-dichlorobenzene and naphthalene residues in honey by gas chromatography–mass spectrometry using purge and trap thermal desorption extraction

A highly sensitive method for the determination of 1,2-dibromoethane, 1,2-dichlorobenzene and naphthalene residues in honey was developed, using gas chromatography-mass spectrometry combined with a purge and trap thermal desorption system as the extraction technique. Optimal conditions for isolation and separation were established and calibration curves were constructed. Linearity was held between 2.4 and 300 microg kg(-1) honey for 1,2-dibromoethane, 0.5 and 300 microg kg(-1) for 1,4-dichlorobenzene and 0.125 and 3000 microg kg(-1) for naphthalene. The detection limits were found to be 0.8, 0.15 and 0.05 microg kg(-1) honey for 1,2-dibromoethane, 1,4-dichlorobenzene and naphthalene, respectively. The method was applied to the analysis of 25 Greek honey samples. 1,2-Dibromoethane was not found in the majority of the samples, while only one sample was found to contain both 1,4-dichlorobenzene and naphthalene residues at concentrations exceeding 10 microg kg(-1).

A rapid capillary electrophoresis with electrochemiluminescence method for the assay of human urinary proline and hydroxyproline

A novel simultaneous determination method for free and total proline (Pro) and hydroxyproline (Hyp) in human urine was developed, based on capillary electrophoresis (CE) with electrochemiluminescence (ECL) detection, using tris-(2,2'-bipyridyl) ruthenium(II). Experimental conditions, such as the Ru(bpy)(3)2+ concentration, detection potentials, buffer concentration and pH in CE or in the ECL cell, injection voltage and time were investigated in detail. Under optimized conditions, the linear range, detection limit and sample recoveries for the method were 0.01-2 mmol/L (correlation coefficient, 0.9970), 4 micromol/L and 96.4-101.2% in human urine, respectively. The results show that the method has potential applications in monitoring the level of Pro and Hyp in body fluids from patients with bone disease, tumours or chronic uraemia.